Introduction
============

Hepatocellular carcinoma (HCC) is a highly aggressive cancer, characterized by the activation of multiple molecular pathways [@B1], [@B2]. It is the sixth most common cancer and the third most common cause of cancer-related deaths worldwide [@B3]. China alone accounts for 55% of the world\'s cases because of the high prevalence of chronic hepatitis B virus (HBV) infection and liver cirrhosis, both significant risk factors for the disease [@B3]. Currently, liver transplantation (LT) is the only potentially curative therapeutic modality that can treat both the cancer and the associated liver dysfunction simultaneously. But while LT offers a reasonable survival benefit for selected patients with HCC and end-stage liver disease [@B4], [@B5], the long-term survival of patients following surgery remains unsatisfactory because of the high frequency of recurrence due to metastasis - principally attributed to the presence of microscopic extrahepatic metastatic foci before LT [@B6]. Therefore, a better understanding of the molecular mechanisms underlying HCC recurrence may offer improved diagnostic and prognostic capabilities in addition to the development of effective novel therapeutic strategies.

The hepatocyte growth factor (HGF)-MET pathway is primarily involved in regulating cell proliferation, motility, and invasion [@B7]. Dysregulation of HGF-MET signaling leading to tumorigenesis and metastasis has been described in various types of cancer, including HCC [@B8], [@B9]. Emerging evidence suggests that aberrant activation of the HGF-MET signaling pathway is closely associated with malignant transformation and the metastatic potential of HCC [@B2]. So understanding events both upstream and downstream of HGF-MET signaling might reveal new strategies to tackle HCC.

Recent investigations have revealed that the metastasis-associated in colon cancer-1 (MACC1) is a key regulator of HGF-MET signaling in colorectal cancer cells; regulation is achieved by transcriptionally upregulating the expression of MET [@B10]. MACC1-mediated activation of the HGF-MET signaling cascade could enhance the metastatic ability of colon cancer cells. MACC1 is a marker for advanced colorectal cancer and peritoneal disseminated gastric carcinoma, and it could be used to identify patients with a poor prognosis [@B10], [@B11]. Our previous study identified that MACC1 promotes cell survival and metastasis in HCC and MACC1 acts as a key factor regulating HGF/MET and FAK signaling network. MACC1 expression has been shown to correlate with vascular invasive HCC and other studies suggest that its expression correlates with prognosis in HBV-related HCC [@B11]-[@B13]. However, the predictive value of MACC1, combined with its target gene MET and FAK, for HCC after LT remains unclear.

In this study, we investigated the expression pattern of MACC1, MET and FAK in HCC and analyzed its clinicopathological significance, and determined whether MACC1, MET and FAK could be important prognostic factors for predicting clinical outcomes in HCC patients treated with LT.

Materials and methods
=====================

Patients and samples
--------------------

One hundred and sixty HCC patients who underwent LT during 2001 and 2010 in the First Affiliated Hospital of Zhejiang University School of Medicine were enrolled in this study. The eligibility criteria of the study patients were as follows: (a) HCC was diagnosed either before or after transplantation (as an incidental finding). The diagnoses were confirmed by pathologic examination; (b) all patients were HBV infected; (c) clinicopathologic variables, such as vascular invasion, preoperative alpha-fetoprotein (AFP), and tumor size were completely recorded; (d) pretransplant tumor therapies included liver resection, transarterial chemoembolization, radiofrequency ablation, and ethanol ablation. The clinicopathologic characteristics of the patients were shown in Table [1](#T1){ref-type="table"}. Specimens of cancer tissues and clinical information were available from these patients after obtaining informed consent. This study was approved by the ethical review committee of the First Affiliated Hospital, School of Medicine, Zhejiang University, and the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki.

Follow up
---------

The follow-up course and diagnostic criteria of recurrence have been described as previous [@B14], briefly, the patients were followed up closely at the outpatient clinic from the date of operation to that of death or the last follow up, and tumor recurrence was monitored by AFP, ultrasonography, chest X-ray, and Emission computed tomography every 3 months for the first 2 years and every 6 months thereafter. Recurrence was diagnosed by imaging techniques, either intrahepatically or extrahepatically. The median follow up was 24 months.

Quantitative real-time reverse-transcription polymerase chain reaction (qPCR)
-----------------------------------------------------------------------------

Total RNA was extracted with TRIzol (Invitrogen, Carlsbad, CA). RNA was purified using the RNeasy mini kit, RNeasy micro kit and RNase-Free DNase Set(Qiagen Sciences Inc, Germantown, MD) and its quality was assessed with an Agilent Bioanalyzer Nano Chip 2100 (Agilent, Foster City, CA).

The messenger RNA (mRNA) expression levels of MACC1, MET and focal adhesion kinase (FAK) in the HCC tissues and cell lines were determined by qPCR, and the primer sequences were listed in Table [2](#T2){ref-type="table"}. qPCR reactions were performed by the ABI7500 system (Applied Biosystems, CA) according to the manufacturer\'s instructions. β-actin and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were used as internal control. Expression levels of MACC1, MET and FAK were calculated using the 2exp(-ΔΔCt) formula, and then normalized to the internal control.

Statistical analysis
--------------------

Results were expressed as mean ± standard deviation (SD), as appropriate. Comparisons of continuous data were analyzed by the Student t test between two groups, whereas categorical data were analyzed assessed by the Chi-square test. Overall survival and cumulative recurrence rates were analyzed by the Kaplan-Meier method and the differences between groups were estimated by the log-rank test. Independent prognostic indicators were assessed in the univariate and multivariate analysis using Cox\'s proportional hazard model. Statistical analyses were performed using SPSS for Windows v.16.0 (SPSS, Chicago, IL) and GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA). *P \< 0.05*was considered statistically significant.

Results
=======

Expression of MACC1 and combined expression of MACC1 and FAK are correlated with poor prognosis in HCC patients after LT
------------------------------------------------------------------------------------------------------------------------

To explore whether MACC1 and its downstream genes could be candidate biomarkers in predicting clinical outcome of HCC patients following LT, we examined the expression of MACC1, MET and FAK in 160 HCC samples. Patients were segregated into high/low expression groups based on Receiver Operating Characteristics analysis. Upon clinico-pathological correlation analysis, clinical characteristics, including age, gender, tumor differentiation, vascular invasion, preoperative alphafetoprotein (AFP) level, tumor number, tumor size, Milan criteria or UCSF criteria were not directly related to the expression of MACC1 and MET, while high expression of FAK was significantly correlated with vascular invasion (*P* = 0.039) (Table [1](#T1){ref-type="table"}).

Univariate analysis revealed that vascular invasion, preoperative serum AFP level (\>400 ng/ml), multiple tumors and tumor size (\>5cm) were predictors for overall survival (OS) and cumulative recurrence (Table [3](#T3){ref-type="table"}). Patients with MACC1-high HCC had significantly worse prognosis than those with MACC1-low (Table [3](#T3){ref-type="table"}). The 1-year, 3-year, and 5-year cumulative recurrence rates of MACC1-high HCC were much higher than those of MACC1-low HCC (*P* \< 0.001; Fig. [1](#F1){ref-type="fig"}A). The 1-year, 3-year, and 5-year overall survival rates of patients with MACC1-high HCC were significantly lower than those of patients with MACC1-low HCC (*P* = 0.001; Fig. [1](#F1){ref-type="fig"}B). When the patients were stratified according to the criteria whether matched UCSF criteria or exceeded the criteria, those with increased MACC1 expression revealed a significantly shorter overall survival and higher cumulative recurrence rates (Fig. [2](#F2){ref-type="fig"}). In addition, expression of FAK was also found to be correlated with cumulative recurrence rates and OS (Table [3](#T3){ref-type="table"}; Fig. [1](#F1){ref-type="fig"}C, D), while MET expression had no prognostic significance. When evaluating the combined effect of MACC1 and FAK on prognosis of HCC, we found that the 1-year, 3-year, and 5-year cumulative recurrence rates in the MACC1^low^/FAK^low^ patients were significantly lower than that in the MACC1^high^/FAK^high^ patients. The 1-year, 3-year, and 5-year OS in the MACC1^low^/FAK^low^ patients were significantly higher than those in the MACC1^high^/FAK^high^ patients (Table [3](#T3){ref-type="table"}; Fig. [1](#F1){ref-type="fig"}E, F).

Cox multivariate analysis revealed that, apart from vascular incasion, high preoperative AFP level (\>400 ng/ml), and a larger tumor size (\>5cm), MACC1 overexpression in HCC, rather than FAK, was an independent prognostic factor for predicting tumor recurrence (*P* \< 0.001) and OS (*P* \< 0.001) in HCC patients after LT. When MACC1 was combined with FAK, we found that MACC1/FAK was also an independent prognostic predictor for both OS (*P* \< 0.001) and cumulative recurrence (*P* \< 0.001) (Table [3](#T3){ref-type="table"}).

Discussion
==========

Hepatocellular carcinoma is a highly aggressive malignancy with a complex spectrum of molecular aberrations [@B15]. Liver transplantation offers a viable option for treating selected HCC patients. However, the clinical outcome remains challenging due to the tumor recurrence post-LT [@B16]-[@B18]. Recurrence is principally attributable to the presence of microscopic extrahepatic metastatic foci before LT [@B4]. Improved understanding of the underlying molecular mechanisms governing cancer metastasis is highly desirable.

Metastasis is a complicated process involving multiple steps, and multiple oncoproteins are documented to play important roles in this process [@B19], [@B20]. Recently, overexpression of MACC1 has been correlated with the metastasis of several malignancies [@B10]-[@B13], [@B21]. In the previous study, we identified for the first time that MACC1 promotes cell survival and metastasis in HCC, and overexpression of MACC1 is correlated with a more undifferentiated tumor phenotype. Our previous study reveals a novel molecular mechanism in HCC that MACC1 acts as a key factor for regulating both FAK and HGF/MET signaling network. In the present research, we identified for the first time that MACC1 alone or a combination with FAK could serve as a prognostic predictor for patients with HCC who have undergone LT therapy.

The gene encoding the hepatocyte growth factor (HGF) receptor, MET, is a transcriptional target of MACC1 [@B10]. In addition, HGF activates FAK in normal and cancer cells, suggesting a possible synergism between FAK and HGF signaling [@B22]-[@B24]. All of these suggest that there exist a regulatory network, in which MACC1 modulates and maintains the malignant phenotype of HCC cells. FAK was identified as a key signaling protein mediating the cross talk between adhesion-dependent signaling and growth factor receptors [@B25]-[@B27]. In addition, FAK activation is a key step to epithelial mesenchymal transition (EMT) [@B28]-[@B30]; as we known, progression toward malignancy is accompanied by loss of epithelial differentiation and a shift towards a mesenchymal phenotype, which referred to as EMT [@B31].

The previous in vitro findings indicate that MACC1 has a crucial role in HCC progression and metastasis. We then examined the expression of MACC1 and its downstream genes MET and FAK using a large cohort of clinical HCC samples, and investigated their clinical implications. Multivariate analyses revealed that MACC1 expression was a powerful independent prognostic factor. Interestingly, in patients who matched UCSF criteria, those with increased MACC1 expression were prone to earlier tumor recurrence and shorter OS following LT. This indicates that MACC1 expression may provide additional prognostic values in HCC patients within UCSF criteria. For patients exceeding the Milan or UCSF criteria, measuring the expression of MACC1 could also be helpful to identify prognosis distinguishable subgroup in advanced HCC patients beyond the Milan or UCSF criteria. The qRT-PCR results revealed a positive correlation between MACC1 and its target gene FAK, in addition to the findings that MACC1^high^ or FAK^high^ patients had an increasing risk of tumor recurrence and shorter OS post-LT. Therefore, we made comparisons of prognosis among four subgroups (MACC1^low^/FAK^low^, MACC1^low^/FAK^high^, MACC1^high^/FAK^low^, and MACC1^high^/FAK^high^). The HCC patients with MACC1^low^/FAK^low^ had the most favorable prognosis. Although expression of MACC1 was an independent predictor for OS and cumulative recurrence, the predictive range of MACC1/FAK was more sensitive than that of MACC1 alone. Taken together, these clinical findings implicate that MACC1 alone or combination of MACC1/FAK could be a novel biomarker for predicting metastatic recurrence of HCC in patients following LT, which in turn may influence their overall survival.

Clinicopathological variables including tumor size, tumor grade, microscopic/macroscopic vascular invasion, and alpha-fetoprotein, were important prognostic factors for tumor recurrence in HCC patients post-LT [@B16]-[@B18]. However, the current predictive model based on clinicopathological characteristics is still unsatisfactory and molecular-based tumor staging is critical for individualized diagnosis and therapy [@B32], [@B33]. Our findings demonstrate MACC1 or combination of MACC1/FAK as a complement to predict the prognosis of HCC following LT. Despite an important role of MACC1 in tumor progression and its predictive implication, the study should therefore be viewed as hypothesis generating, to be followed by larger prospective studies to confirm our findings.

In conclusion, MACC1 alone or combination of MACC1 with FAK could serve as a novel biomarker in predicting the prognosis of HCC after liver transplantation and might be a promising new therapeutic target. HCC is a highly aggressive tumor of diverse etiology and complex molecular alterations, an in-depth understanding of the regulation and functions of key oncoproteins such as MACC1 in HCC could have a profound impact on both diagnosis and treatment of this disease.
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![MACC1 expression is correlated with poor prognosis in HCC patients following liver transplantation. Prognostic significance of MACC1 and FAK were assessed by Kaplan-Meier analysis and log-rank tests. The patients whose HCC tissue samples expressed high levels of MACC1 had a poor prognosis with respect to cumulative recurrence (A) and overall survival (B). HCC samples with high FAK expression presented with high cumulative recurrence rates (C) and poor overall survival (D). Upon evaluation of the combined expression of MACC1 and FAK in the prognosis of HCC after LT, MACC1^low^/FAK^low^ was associated with the most favorable prognosis with respect to cumulative recurrence rates (E) and overall survival rates (F) in the four subgroups. I, MACC1^low^/FAK^low^; II, MACC1^low^/FAK^high^; III, MACC1^high^/FAK^low^; and IV, MACC1^high^/FAK^high^.](ijmsv11p0268g001){#F1}

![Prognostic significance of MACC1 in HCC patients stratified according to the Milan or UCSF criteria. Kaplan-Meier analysis of the cumulative recurrence rates (A) and overall survival (B) based on MACC1 expression in HCC patients within Milan criteria. The cumulative recurrence rates (C) and overall survival (D) based on MACC1 expression in HCC patients beyond Milan criteria. The cumulative recurrence rates (E) and overall survival (F) based on MACC1 expression in HCC patients within UCSF criteria. The cumulative recurrence rates (G) and overall survival (H) based on MACC1 expression in HCC patients beyond UCSF criteria.](ijmsv11p0268g002){#F2}

###### 

Correlation between MACC1, MET, or FAK expression and clinicopathological factors in 160 HCC tumors.

                               MACC1 expression        MET expression        FAK expression                     
  ---------------------------- ------------------ ---- ---------------- ---- ---------------- ------- ---- ---- -------
  Age, years                                                                                                    
  \<50                         40                 43   0.072            40   43               0.609   40   43   0.884
  ≥50                          48                 29                    34   43                       38   39   
  Gender                                                                                                        
  Female                       9                  5    0.465            6    8                0.790   7    7    0.922
  Male                         79                 67                    68   78                       71   75   
  Preoperative tumor therapy                                                                                    
  No                           61                 56   0.230            54   63               0.968   59   58   0.484
  Yes                          27                 16                    20   23                       19   24   
  Tumor size                                                                                                    
  ≤5 cm                        49                 43   0.607            43   49               0.885   47   45   0.492
  \>5 cm                       39                 29                    31   37                       31   37   
  Tumor number                                                                                                  
  Single                       40                 30   0.631            32   38               0.905   37   33   0.359
  Multiple                     48                 42                    42   48                       41   49   
  Tumor differentiation                                                                                         
  Well+moderate                49                 39   0.848            42   46               0.679   38   50   0.119
  Poor                         39                 33                    32   40                       40   32   
  Preoperative AFP                                                                                              
  ≤400 ng/ml                   40                 32   0.898            32   40               0.679   41   31   0.061
  \>400 ng/ml                  48                 40                    42   46                       37   51   
  Vascular invasion                                                                                             
  None                         59                 43   0.338            50   52               0.351   56   46   0.039
  Yes                          29                 29                    24   34                       22   36   
  Milan criteria                                                                                                
  Within                       32                 23   0.558            27   28               0.602   30   25   0.288
  Beyond                       56                 49                    47   58                       48   57   
  UCSF criteria                                                                                                 
  Within                       39                 27   0.383            31   35               0.878   37   29   0.121
  Beyond                       49                 45                    43   51                       41   53   

Patients with HCC who underwent LT were segregated into MACC1-low/high expression groups, MET-low/high expression groups, and FAK-low/high expression groups based on receiver operating characteristics analysis (MACC1 cut-off point 1.45, MET cut-off point 2.67, FAK cut-off point 3.28).

Apart from the presence of macrovascular invasion, the Milan criteria are matched if a single tumor is ≤ 5 cm in diameter or if there are ≤ 3 tumor nodules, each of which is 3 cm or less in diameter. The UCSF criteria are matched if a single tumor is ≤ 6.5 cm or if 2-3 lesions are each ≤ 4.5 cm with a total tumor diameter of ≤ 8 cm[@B18].

Abbreviations: MACC1, metastasis-associated in colon cancer-1; FAK, focal adhesion kinase; AFP, alpha-fetoprotein.

\*Statistical analyses were performed with the Chi-square test.

###### 

Oligonucleotides Used for qRT-PCR

  Genes             Sequence(5\'-3\')
  ------- --------- ----------------------------
  MACC1   Forward   TCGGTCAGGAAGAATTGCAC
          Reverse   TTGTGAAGCAAGTCTGGGTCC
  MET     Forward   GCTAAAATGCTGGCACCCTAA
          Reverse   ATAGTGCTCCCCAATGAAAGTAGAGA
  FAK     Forward   TCCCTATGGTGAAGGAAGT
          Reverse   TTCTGTGCCATCTCAATCT
  GAPDH   Forward   GCTGAGAACGGGAAGCTTGT
          Reverse   GCCAGGGGTGCTAAGCAG

###### 

MACC1 expression is an independent prognostic factor for HCC patients following LT.

  -------------------------------------------------------------------------------------------------------------------------
                                                Cumulative recurrence   Overall survival                         
  --------------------------------------------- ----------------------- ------------------ --------------------- ----------
  **Univariate analysis**†                                                                                       

  Age, year (≥50 versus \<50)                   0.546 (0.355-0.841)     0.006              0.808 (0.521-1.253)   0.341

  Gender (male versus female)                   2.161 (0.834-5.095)     0.117              2.654 (0.970-7.261)   0.057

  Preoperative treatment (yes versus no)        1.196 (0.747-1.916)     0.457              1.025 (0.617-1.703)   0.924

  Tumor size (\>5 cm versus ≤5 cm)              3.934 (2.527-6.123)     \< 0.001           3.070 (1.960-4.809)   \< 0.001

  Tumor number (multiple versus single)         2.595 (1.637-4.114)     \< 0.001           2.356 (1.468-3.779)   \< 0.001

  Tumor differentiation\                        1.485 (0.947-2.265)     0.066              1.043 (0.672-1.620)   0.851
  (poor versus well+moderate)                                                                                    

  Preoperative AFP, ng/ml (\>400 versus ≤400)   2.261 (1.440-3.548)     \< 0.001           1.820 (1.151-2.878)   0.010

  Vascular invasion (yes versus none)           2.995 (1.959-4.580)     \< 0.001           2.310 (1.491-3.579)   \< 0.001

  MACC1^high^ versus MACC1^low^                 2.193 (1.430-3.364)     \< 0.001           2.127 (1.362-3.322)   0.001

  MET^high^ versus MET^low^                     1.460 (0.951-2.242)     0.084              1.369 (0.878-2.133)   0.166

  FAK^high^ versus FAK^low^                     1.858 (1.204-2.867)     0.005              1.613 (1.035-2.514)   0.035

  Combination of MACC1 and FAK                                          \< 0.001                                 \< 0.001

  II versus I                                   2.722 (1.399-5.296)     0.003              2.185 (1.088-4.387)   0.028

  III versus I                                  3.602 (1.809-7.174)     \< 0.001           3.001 (1.509-5.970)   0.002

  IV versus I                                   3.478 (1.884-6.420)     \< 0.001           2.904 (1.566-5.383)   0.001

  **Multivariate analysis**†                                                                                     

  Age, year (≥50 versus \<50)                   \-                      0.153              \-                    \-

  Tumor size (\>5 cm versus ≤5 cm)              3.350 (2.123-5.288)     \< 0.001           2.719 (1.725-4.286)   \< 0.001

  Tumor number (multiple versus single)         \-                      0.141              \-                    0.150

  Preoperative AFP, ng/ml\                      1.789 (1.130-2.833)     0.013              1.624 (1.020-2.587)   0.041
  (\>400 versus ≤400)                                                                                            

  Vascular invasion (yes versus none)           2.267 (1.474-3.485)     \< 0.001           1.853 (1.192-2.880)   0.006

  MACC1^high^ versus MACC1^low^                 2.495 (1.616-3.851)     \< 0.001           2.280 (1.453-3.580)   \< 0.001

  FAK^high^ versus FAK^low^                     \-                      0.127              \-                    0.136

  Combination of MACC1 and FAK                  \-                      \< 0.001           \-                    \< 0.001

  II versus I                                   2.518 (1.286-4.929)     0.007              2.116 (1.048-4.274)   0.037

  III versus I                                  3.444 (1.707-6.948)     0.001              3.001 (1.509-5.970)   0.002

  IV versus I                                   3.902 (2.078-7.328)     \< 0.001           3.381 (1.809-6.316)   \< 0.001
  -------------------------------------------------------------------------------------------------------------------------

Abbreviations: MACC1, metastasis-associated in colon cancer-1; FAK, focal adhesion kinase; AFP, alpha-fetoprotein; 95% CI, 95% confidence interval.

†Statistical analyses were performed by Cox proportional hazards regression (univariate and multivariate analysis).

I, MACC1^low^/FAK^low^; II, MACC1^low^/FAK^high^; III, MACC1^high^/FAK^low^; IV, MACC1^high^/FAK^high^.
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